PROS1 and viral infectious disease: Most, if not all, nAbs specific to the SARS-CoV-2 S protein RBD potently neutralize wild-type SARS-CoV-2 pseudovirus and/or live virus infection in vitro, and they present more potent neutralizing activity than nAbs targeting non-RBD epitopes.